Citigroup Inc Bei Gene, Ltd. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Citigroup Inc holds 26,312 shares of BGNE stock, worth $5.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,312

Previous 20,902 25.88%

Holding current value

$5.05 Million

Previous $2.98 Million 98.09%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$143.93 - $224.51 $778,661 - $1.21 Million	5,410 Added 25.88%	26,312 $5.91 Million
Q2 2024 Aug 12, 2024	BUY	$129.52 - $174.32 $1.65 Million - $2.21 Million	12,701 Added 154.87%	20,902 $2.98 Million
Q1 2024 May 10, 2024	BUY	$141.8 - $181.47 $416,041 - $532,432	2,934 Added 55.71%	8,201 $1.28 Million
Q4 2023 Feb 09, 2024	BUY	$158.67 - $201.58 $397,944 - $505,562	2,508 Added 90.9%	5,267 $949,000
Q3 2023 Nov 09, 2023	SELL	$179.87 - $225.13 $89,035 - $111,439	-495 Reduced 15.21%	2,759 $496,000
Q2 2023 Aug 10, 2023	BUY	$178.3 - $266.78 $87,545 - $130,988	491 Added 17.77%	3,254 $580,000
Q1 2023 May 11, 2023	BUY	$215.53 - $274.5 $84,272 - $107,329	391 Added 16.48%	2,763 $595,000
Q4 2022 Feb 09, 2023	SELL	$125.51 - $229.3 $944,462 - $1.73 Million	-7,525 Reduced 76.03%	2,372 $521,000
Q3 2022 Nov 10, 2022	SELL	$131.8 - $202.24 $922,468 - $1.42 Million	-6,999 Reduced 41.42%	9,897 $1.34 Million
Q2 2022 Aug 10, 2022	SELL	$121.11 - $216.05 $134,432 - $239,815	-1,110 Reduced 6.16%	16,896 $2.74 Million
Q1 2022 May 12, 2022	SELL	$146.52 - $269.56 $1.41 Million - $2.59 Million	-9,619 Reduced 34.82%	18,006 $3.4 Million
Q4 2021 Feb 10, 2022	BUY	$248.56 - $389.34 $563,982 - $883,412	2,269 Added 8.95%	27,625 $7.49 Million
Q3 2021 Nov 10, 2021	BUY	$249.6 - $403.14 $6.33 Million - $10.2 Million	25,356 New	25,356 $9.21 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account